Skip to main content
Premium Trial:

Request an Annual Quote

Singulex, Dutch Technology Foundation Partner on Center for Biomarker Development

NEW YORK (GenomeWeb) – Singulex today announced a public-private partnership with the Dutch Technology Foundation to create the Biomarker Development Center (BDC). 

Headed by Rainer Bischoff, a professor at the University of Groningen, the center is tasked with accelerating the development and validation of clinical biomarkers. The BDC academic partners will use Singulex's research-use-only Erenna Immunoassay System, based on the firm's Single Molecule Counting technology, to quantify ultra-low level biomarkers, which often circulate at femtogram per milliliter concentrations. They will select, co-develop, and validate the biomarkers for potential use in clinical applications, Singulex said. 

BDC, funded in part by the Dutch Technology Foundation, along with industry partners, received a grant to develop and validate candidate biomarkers specifically for type 2 diabetes, Alzheimer's disease, and chronic obstructive pulmonary disease. Bischoff is joined in the initiative by researchers from Radboud University Medical Center in Nijmegen, Erasmus Medical Center in Rotterdam, and University Medical Center Groningen. 

"This strategic alliance furthers our mission to improve healthcare by applying innovative tools in disease areas that would be better served by more quantitative and more disease-specific diagnostic offerings," Paul Wheeler, VP of life science sales and marketing at Alameda, Calif.-based Singulex, said in a statement. 

The center expects to begin testing available biomarkers later this year, Singulex said. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.